Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| 1 |
Booking.com
BKNG
|
$551M |
| 2 |
Meta Platforms (Facebook)
META
|
$407M |
| 3 |
Align Technology
ALGN
|
$382M |
| 4 |
United Parcel Service
UPS
|
$310M |
| 5 |
PayPal
PYPL
|
$291M |
Top Sells
| 1 |
Apple
AAPL
|
$598M |
| 2 |
Alibaba
BABA
|
$570M |
| 3 |
Altria Group
MO
|
$408M |
| 4 |
Revvity
RVTY
|
$350M |
| 5 |
Merck
MRK
|
$320M |
Sector Composition
| 1 | Technology | 30.77% |
| 2 | Healthcare | 19.73% |
| 3 | Consumer Discretionary | 11.52% |
| 4 | Financials | 9.59% |
| 5 | Communication Services | 8.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
Amicus Therapeutics
FOLD
$2.46B
| $199M | 0.1% |
14,106,259
+2,312,500
| +20% | +$32.7M |
|
202
Royalty Pharma
RPRX
$15.6B
| $199M | 0.1% |
4,724,644
+217,506
| +5% | +$9.15M |
|
|
GWPH
203
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $199M | 0.1% |
2,041,289
+319,972
| +19% | +$31.2M |
|
204
Insmed
INSM
$30.7B
| $198M | 0.1% |
6,169,167
-3,073,205
| -33% | -$98.8M |
|
205
Union Pacific
UNP
$131B
| $197M | 0.1% |
1,000,392
+206,001
| +26% | +$40.6M |
|
|
RP
206
DELISTED
RealPage, Inc.
RP
| $196M | 0.1% |
3,395,193
-547,783
| -14% | -$31.6M |
|
207
Illumina
ILMN
$15.7B
| $196M | 0.1% |
650,548
+349,485
| +116% | +$105M |
|
208
Caesars Entertainment
CZR
$5.48B
| $195M | 0.1% |
3,475,888
+2,867,568
| +471% | +$161M |
|
209
Elevance Health
ELV
$70.6B
| $192M | 0.1% |
714,583
-74,263
| -9% | -$19.9M |
|
210
Integra LifeSciences
IART
$1.25B
| $191M | 0.1% |
4,049,872
-145,314
| -3% | -$6.86M |
|
211
Regeneron Pharmaceuticals
REGN
$60.8B
| $191M | 0.1% |
341,587
+46,572
| +16% | +$26.1M |
|
212
CVS Health
CVS
$93.6B
| $191M | 0.1% |
3,272,041
+1,256,506
| +62% | +$73.4M |
|
213
Kraft Heinz
KHC
$32.3B
| $189M | 0.1% |
6,301,899
+2,172,899
| +53% | +$65.1M |
|
214
Clorox
CLX
$15.5B
| $188M | 0.1% |
893,649
+29,318
| +3% | +$6.16M |
|
215
Visteon
VC
$3.41B
| $186M | 0.1% |
2,683,100
-8,199
| -0.3% | -$568K |
|
216
Pfizer
PFE
$141B
| $186M | 0.1% |
5,329,128
-489,319
| -8% | -$17M |
|
217
Berkshire Hathaway Class B
BRK.B
$1.08T
| $185M | 0.1% |
868,641
-40,466
| -4% | -$8.62M |
|
218
West Pharmaceutical
WST
$18B
| $185M | 0.1% |
671,942
+43,155
| +7% | +$11.9M |
|
219
Bio-Techne
TECH
$8.46B
| $184M | 0.1% |
2,963,284
-406,064
| -12% | -$25.1M |
|
220
Parker-Hannifin
PH
$96.1B
| $180M | 0.09% |
890,403
-28,571
| -3% | -$5.78M |
|
221
MSCI
MSCI
$42.9B
| $180M | 0.09% |
503,248
-6,201
| -1% | -$2.21M |
|
222
ServiceNow
NOW
$190B
| $179M | 0.09% |
368,187
-40,615
| -10% | -$19.7M |
|
|
ALXN
223
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $177M | 0.09% |
1,547,353
+1,313,698
| +562% | +$150M |
|
224
Blackbaud
BLKB
$3.23B
| $176M | 0.09% |
3,145,087
-12,861
| -0.4% | -$718K |
|
225
Garmin
GRMN
$45.7B
| $174M | 0.09% |
1,839,528
+112,201
| +6% | +$10.6M |
|